Patient Access Insights

Pricing and policy for Market Access

In this webinar, the panel of experts explore the latest pricing and policy insights for accelerating patient access.
Request this webinar

Pricing and policy for Market Access

Originally broadcast: Tuesday 29th September 2020

Duration: 90 minutes. Available to watch on demand

Learning objectives:

  •  Understand commercial and Managed Access in England

  •  Update on VPAS – what you need to know

  •  Pricing for Advanced Therapy Medicinal Products

  •  How to respond to new high cost/high value drugs

  •  Get the latest pricing and policy insights for accelerating patient access


Who would benefit from registering to attend this webinar:

This webinar should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.

The job functions that will benefit most include:

• Heads of Market Access

• Managing Directors

• Country Managers

• Chief Executives

• Health Economists

• Medical Directors

• Commercial Directors

• Policy Officers/Executives

• Marketing Directors

• Policy Advisors



Speakers

Speaker%20picture%20 %20David%20Watson

David Watson, Executive Director: Economic, Health and Commercial Policy, Association of the British Pharmaceutical Industry (ABPI)

David Watson is currently the interim Executive Director, Economic, Health and Commercial Policy at the ABPI. David was previously the ABPI Commercial Policy Director leading on the Voluntary Scheme. David joined the ABPI in May 2014 from a consulting background and prior to that spent many years at Pfizer where he held a series of roles including European Head of Business Intelligence, channel strategy, and a variety of sales and marketing positions in the UK and the Pfizer European business.

Speaker%20picture%20 %20Carla%20Deakin

Carla Deakin, Programme Director, Commercial & Managed Access, NICE

Having gained extensive experience in Healthcare Sales and Marketing, Carla’s more recent interests and activities have focused around the changing UK healthcare delivery system and how to evidence the value In - Vitro diagnostics can bring. She has held senior positions at NICE including Associate Director for Market Access and Associate Director for Diagnostic Assessment Programme. Carla is currently the Programme Director for Commercial & Managed Access.

Christian%20500x500

Christian Hill, CEO, MAP BioPharma

Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.
Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.

Terms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2020. MAP BioPharma Limited. All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

+44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281

VAT Group Registration Number GB 292 8576 52